Search
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia.
Doxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalIt is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair.
Oxacillin
go.drugbank.com/drugs/DB00713ApprovedInvestigationalAn antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.
International brands: Staficilin-NIdoxuridine
go.drugbank.com/drugs/DB00249ApprovedWithdrawnAn analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideEthoxzolamide
go.drugbank.com/drugs/DB00311ApprovedWithdrawnEthoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.
1,2-dichlorobenzene
go.drugbank.com/drugs/DB13963ApprovedWithdrawn1,2-Dichlorobenzene, also named ortho-dichlorobenzene, is an organic compound. It is a non-polar colorless liquid that is miscible in most organic solvents. … insecticide and as an agent to remove carbon-based contamination from metal.
Categories: Compounds used in a research, industrial, or household settingGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalin combination with sofosbuvir for all six genotypes of Hepatitis C [L852]. … It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and
Sulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Mixtures: AMPICILLINA E SULBACTAM IBI, AMPICILLINA E SULBACTAM IBI